Macrophage cell therapies may make headlines this weekend as the first CAR macrophage data in an immunocompetent animal model read out at AACR, but the conference will also showcase a spate of other strategies...

BioCentury’s analysis of this year’s AACR meeting unearths orthogonal approaches to high-wattage targets KRAS and TIGIT, details on allogeneic and personalized cell therapies, and targeted protein degradation players beyond the usual suspects. In the run-up...

Antisense oligonucleotides to treat progeriaTwo NIH teams, one led by NIH director Francis Collins, discovered antisense oligonucleotides (ASOs) against the LMNA gene to treat Hutchinson-Gilford progeria syndrome (HGPS). The disorder is caused by progerin, a...

The launch of an mRNA subsidiary is the latest move by RNAi company OliX to build upon its trio of partnerships and bicoastal beachhead of U.S. offices to realize its global ambitions. OliX Pharmaceuticals...

Bluebird is seeking to resume clinical development and marketing of products based on the BB305 lentiviral vector after largely ruling it out as the cause of cancer in a clinical trial participant, but the case...

With $106 million in new series C funding, Tenaya will internalize its AAV manufacturing capabilities and continue to advance its suite of gene therapy, cellular regeneration and precision medicine platforms for heart disease.  Tenaya Therapeutics...

As regulators embrace platform technologies to rapidly update COVID-19 vaccines, they are laying the groundwork for personalized cancer and rare disease therapies, according to NCI Director Ned Sharpless....

FogPharma will use its venBio-led $107 million series C round to bring its lead program, a cell-permeable CTNNB1 antagonist, into the clinic for cancer. The company, helmed by Chairman, President...

As Kymera becomes the second company to bring a targeted protein degrader to the clinic, the company’s choice to start outside oncology is enabling it to gather a broader array of data than Arvinas’ single-arm,...

Orna emerged from stealth Wednesday with an $80 million A round to develop circular RNA therapies for cancer and genetic diseases that could be easier to manufacture than linear RNAs and immune cell therapies. MPM Capital,...